BTBD2

Across TCGA pan-cancer cohorts, BTBD2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BTBD2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where BTBD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BTBD2 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where BTBD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTBD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.203	<.001	7	view →
LUAD	Female	II,III,IV	+0.297	<.001	6	view →
HNSC	All	All	−0.158	.016	3	view →
PDAC	Male	All	−0.267	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BTBD2–LSCC

Open the LSCC breakdown →